Zentalis Pharmaceuticals, Inc.
No enriched coverage for $ZNTL in the last 7 days.
WALTERS GROUP purchased 4,335,000 shares of Zentalis Pharmaceuticals, Inc. (ZNTL) at $3.50 ($15.17M total) on 2026-08-14. Filed jointly with WALTERS WILLIAM THURMAN (10% owner) and WALTERS SUSAN BERKLEY (10% owner).
Zentalis Pharmaceuticals shares fell about 15% in pre-open trading after the company announced and priced a large underwritten public offering. The deal issues 23 million shares at $3.50 each, with an option for up to 3.45 million more. Gross proceeds are about $80.5 million to fund trials and research for azenosertib.
Zentalis Pharmaceuticals (NASDAQ:ZNTL) shares fell about 6.5% in after-hours after it announced an underwritten public offering of common stock and pre-funded warrants. The company plans to use net proceeds plus existing cash for clinical trials, regulatory filings, manufacturing, and general corporate purposes. Joint bookrunners include TD Cowen, Guggenheim, and Oppenheimer.
Recent ZNTL coverage spans financial news, corporate actions and earnings.
In the last 30 days, ZNTL insiders filed 1 SEC Form 4 transaction — 1 purchase ($15.2M) and no sales. The most active reporter was WALTERS GROUP with 1 filing.
Significant insider buying suggests confidence in Zentalis and may support the stock price.
The dilution from a below-market priced equity raise is the immediate driver of downside risk for ZNTL shares.
The dilutive financing headline is likely to pressure near-term valuation and trading liquidity, with risk tied to deal size and pricing.
FDA alignment on dose and study population plus updated cash runway and DENALI enrollment status are near-term catalysts for biotech risk pricing.
ManpowerGroup reported upbeat Q2 results. Adjusted earnings were 99 cents per share, above analysts’ 95 cents estimate. Revenue increased 8% year over year to $4.86 billion, or 6% in constant currency, versus $4.72 billion expected. ManpowerGroup shares rose 5.8% to $54.63 on Friday.
alphai scores every news story that mentions ZNTL with an AI model for sentiment and relevance, and aggregates insider trades from Zentalis Pharmaceuticals, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
WALTERS GROUP purchased 4,335,000 shares of Zentalis Pharmaceuticals, Inc. (ZNTL) at $3.50 ($15.17M total) on 2026-08-14. Filed jointly with WALTERS WILLIAM THURMAN (10% owner) and WALTERS SUSAN BERKLEY (10% owner).
1 min readZentalis Pharmaceuticals shares fell about 15% in pre-open trading after the company announced and priced a large underwritten public offering. The deal issues 23 million shares at $3.50 each, with an option for up to 3.45 million more. Gross proceeds are about $80.5 million to fund trials and research for azenosertib.
3 min readZentalis Pharmaceuticals (NASDAQ:ZNTL) shares fell about 6.5% in after-hours after it announced an underwritten public offering of common stock and pre-funded warrants. The company plans to use net proceeds plus existing cash for clinical trials, regulatory filings, manufacturing, and general corporate purposes. Joint bookrunners include TD Cowen, Guggenheim, and Oppenheimer.
4 min readZentalis Pharmaceuticals, Inc. (ZNTL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates • Following U.S. regulatory discussions, accelerated approval strategy remains intact, supported by DENALI Part 2 • Enrollment completed in Part 2a and 2b of the DENALI trial;
6 min readManpowerGroup reported upbeat Q2 results. Adjusted earnings were 99 cents per share, above analysts’ 95 cents estimate. Revenue increased 8% year over year to $4.86 billion, or 6% in constant currency, versus $4.72 billion expected. ManpowerGroup shares rose 5.8% to $54.63 on Friday.
2 min readZentalis Pharmaceuticals, Inc. (ZNTL) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. zntl-20260616 0001725160 FALSE 0001725160 2026-06-16 2026-06-16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 —————————————— FORM 8-K —————————————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Dat
3 min readZentalis Pharmaceuticals (Nasdaq: ZNTL) said its Compensation Committee granted non-qualified stock options to two newly hired employees on June 1, 2026, totaling 191,000 shares under Nasdaq Listing Rule 5635(c)(4). Options have a $3.98 exercise price, a 10-year term, and 4-year vesting (25% at year one, then monthly over three years), subject to continued service.
2 min readSAN DIEGO, Nov. 03, 2025 ( GLOBE NEWSWIRE ) -- Zentalis® Pharmaceuticals, Inc. ( Nasdaq: ZNTL ) , a clinical-stage biopharmaceutical company developing a potentially first-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on November 3, 2025, ...
2 min readSAN DIEGO, Nov. 03, 2025 ( GLOBE NEWSWIRE ) -- Zentalis® Pharmaceuticals, Inc. ( Nasdaq: ZNTL ) , a clinical-stage biopharmaceutical company developing a potentially first-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that members of the ...
2 min readSAN DIEGO, Oct. 01, 2025 ( GLOBE NEWSWIRE ) -- Zentalis® Pharmaceuticals, Inc. ( NASDAQ:ZNTL ) , a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on ...
2 min read
